|
|
Article: Corixa Announces Initiation of Phase I Clinical Trial of CRX-675 in Patients with Seasonal Allergic Rhinitis.
- Article from:
- Business Wire
- Article date:
- April 26, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
SEATTLE--(BUSINESS WIRE)--April 26, 2004
TLR4 Agonist Product Candidate First to Enter Clinic
From Corixa's Innate Immunity Program
Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, today announced the initiation of a Phase I clinical trial to test the safety and immune response activity of CRX-675 for seasonal allergic rhinitis (SAR). The trial is being conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND). CRX-675 is a member of Corixa's family of proprietary compounds that interact with toll-like receptor 4 ...